235 related articles for article (PubMed ID: 21463144)
1. Epothilones in the treatment of ovarian cancer.
Diaz-Padilla I; Oza AM
Future Oncol; 2011 Apr; 7(4):559-68. PubMed ID: 21463144
[TBL] [Abstract][Full Text] [Related]
2. Epothilones: clinical update and future directions.
Donovan D; Vahdat LT
Oncology (Williston Park); 2008 Apr; 22(4):408-16; discussion 416, 421, 424 passim. PubMed ID: 18472615
[TBL] [Abstract][Full Text] [Related]
3. The epothilones: how pharmacology relates to clinical utility.
Michaud LB
Ann Pharmacother; 2009 Jul; 43(7):1294-309. PubMed ID: 19584389
[TBL] [Abstract][Full Text] [Related]
4. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
Rivera E; Lee J; Davies A
Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
[TBL] [Abstract][Full Text] [Related]
5. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
[TBL] [Abstract][Full Text] [Related]
6. Epothilones in the treatment of cancer.
Larkin JM; Kaye SB
Expert Opin Investig Drugs; 2006 Jun; 15(6):691-702. PubMed ID: 16732719
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue].
Villanueva C; Dufresne A; Pivot X; Viel E
Bull Cancer; 2008 Feb; 95(2):197-204. PubMed ID: 18304905
[TBL] [Abstract][Full Text] [Related]
8. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
[TBL] [Abstract][Full Text] [Related]
9. Clinical studies with epothilones for the treatment of metastatic breast cancer.
Vahdat LT
Semin Oncol; 2008 Apr; 35(2 Suppl 2):S22-30; quiz S40. PubMed ID: 18410796
[TBL] [Abstract][Full Text] [Related]
10. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
Vahdat L
Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531
[TBL] [Abstract][Full Text] [Related]
11. Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice setting.
Cigler T; Vahdat L
Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S166-70. PubMed ID: 19158037
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with epothilones in patients with breast cancer.
Buzdar AU
Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S71-8. PubMed ID: 18637402
[TBL] [Abstract][Full Text] [Related]
13. Ixabepilone and other epothilones: microtubule-targeting agents for metastatic breast cancer.
Morris PG; Fornier MN
Clin Adv Hematol Oncol; 2009 Feb; 7(2):115-22. PubMed ID: 19367253
[TBL] [Abstract][Full Text] [Related]
14. Ixabepilone: new drug. Similar to taxanes, but no better.
Prescrire Int; 2009 Aug; 18(102):160. PubMed ID: 19743574
[No Abstract] [Full Text] [Related]
15. Targeting the microtubules in breast cancer beyond taxanes: the epothilones.
Cortes J; Baselga J
Oncologist; 2007 Mar; 12(3):271-80. PubMed ID: 17405891
[TBL] [Abstract][Full Text] [Related]
16. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
Boehnke Michaud L
J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553
[TBL] [Abstract][Full Text] [Related]
17. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
Yardley DA
Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
[TBL] [Abstract][Full Text] [Related]
18. Ixabepilone: a new active chemotherapy in the treatment of breast cancer.
Villanueva C; Vuillemin AT; Demarchi M; Bazan F; Chaigneau L; Pivot X
Womens Health (Lond); 2009 Mar; 5(2):115-21. PubMed ID: 19245349
[TBL] [Abstract][Full Text] [Related]
19. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.
De Geest K; Blessing JA; Morris RT; Yamada SD; Monk BJ; Zweizig SL; Matei D; Muller CY; Richards WE
J Clin Oncol; 2010 Jan; 28(1):149-53. PubMed ID: 19917861
[TBL] [Abstract][Full Text] [Related]
20. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
Brogdon CF; Lee FY; Canetta RM
Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
